ADHD diagnoses surge across Europe driven by awareness, not epidemic

Walk into a clinic in London, Amsterdam, or Madrid these days and you'll hear the same thing: more people are being diagnosed with ADHD than ever before. The referrals keep climbing. The prescriptions keep rising. But here's what the numbers actually show: the condition itself isn't suddenly more common. What's changed is that we're finally seeing it.

Professor Anita Thapar, who chaired the NHS England ADHD taskforce and advised the Welsh Government on neurodivergence, is preparing to tell Europe's leading clinical neuroscience conference exactly this. The surge in diagnoses across the continent, she will argue, reflects not an epidemic but a fundamental shift in how the medical system recognizes and responds to a condition that was always there, largely invisible. "It is now being recognized, whereas in the past it wasn't," Thapar said. The comparison she draws is instructive: in the 1960s, doctors didn't widely understand the risks of high blood pressure or elevated cholesterol either. The diseases didn't suddenly appear when awareness grew—they'd been present all along.

The evidence supporting this view is substantial. Across Europe, the actual prevalence of ADHD in the population has remained stable at roughly 5 to 7 percent of children and 2 to 3 percent of adults. Yet the number of people formally diagnosed and treated varies wildly depending on where they live. In some countries, diagnosed rates now match what researchers expect from the general population. In the UK, by contrast, the rate of recognized cases still falls well below what epidemiologists estimate should be there. This gap itself is telling: it suggests that even with rising diagnoses, ADHD remains substantially under-diagnosed and under-treated in many places.

The medication numbers paint a picture of accelerating recognition, particularly among groups historically overlooked. In the UK, the proportion of the population taking ADHD medication more than tripled between 2010 and 2023, climbing from 0.12 percent to 0.39 percent. Similar increases appeared in Belgium, Germany, the Netherlands, and Spain over the same period. What stands out is the trajectory among women and adults—populations that received little clinical attention in earlier decades. The medical field is now grappling with evidence that ADHD affects women and girls at rates previously missed, and that the condition persists well into adulthood, something earlier diagnostic frameworks largely ignored.

Thapar points to several concrete reasons for the shift. Diagnostic criteria have evolved. Public awareness has grown. Research has accumulated showing that untreated ADHD carries real risks—premature mortality, suicide, accidents. As that evidence accumulated, the threshold for intervention moved, just as it did for blood pressure and cholesterol management. Guidelines now typically recommend starting with behavioral support and moving to medication only if other strategies prove insufficient. The definition of ADHD itself has become more nuanced: it's not a binary yes-or-no condition but exists along a spectrum, and the point at which doctors decide treatment is warranted can shift as knowledge deepens.

Concerns about misdiagnosis do circulate, but Thapar notes that research evidence on this question remains limited. What is clear is that the current system is catching fewer cases than it should. The rate at which ADHD appears in clinical settings is lower than population estimates suggest it should be, indicating that many people who could benefit from assessment and support are still not reaching diagnosis. This variation across European countries reflects not differences in how common ADHD is, but differences in service capacity, access to assessment, and clinical practice patterns.

Professor Barbara Franke of Radboud University in the Netherlands, speaking independently, underscores the paradox: researchers have spent years documenting that ADHD is underdiagnosed in women and adults, and now that message is finally reaching the public and the profession—but the speed of the shift can feel disorienting, almost like an epidemic. Yet despite the high prevalence and the documented burden the condition creates, funding for ADHD research remains surprisingly scarce. It remains, she notes, one of medicine's most under-researched conditions.

The conversation now shifts to how healthcare systems respond. Referrals are climbing. Demand is outpacing capacity in many places. The challenge ahead is not to slow diagnosis but to ensure that rising numbers translate into appropriate assessment and genuine support, while continuing to identify the people still being missed. The session at the European College of Neuropsychopharmacology congress in Munich will be an open discussion on exactly this question: what's driving the increase, and how should systems adapt?